[1] RIAZI K, AZHARI H, CHARETTE J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9):851-861. doi:  10.1016/S2468-1253(22)00165-0
[2] LONARDO A, LEONI S, ALSWAT K A, et al. History of Nonalcoholic Fatty Liver Disease[J]. Int J Mol Sci, 2020, 21(16):5888. doi:  10.3390/ijms21165888
[3] DAY C P, JAMES O F. Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4):842-845. doi:  10.1016/S0016-5085(98)70599-2
[4] BUZZETTI E, PINZANI M, TSOCHATZIS E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048. doi:  10.1016/j.metabol.2015.12.012
[5] LEE J, VALI Y, BOURSIER J, et al. Accuracy of cytokeratin 18(M30 and M65)in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis[J]. PLoS One, 2020, 15(9):e0238717. doi:  10.1371/journal.pone.0238717
[6] YANG M, XU D, LIU Y, et al. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis[J]. PLoS One, 2015, 10(6):e0131664. doi:  10.1371/journal.pone.0131664
[7] CAO W, ZHAO C, SHEN C, et al. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis[J]. PLoS One, 2013, 8(12):e82092. doi:  10.1371/journal.pone.0082092
[8] KAMADA Y, FUJII H, FUJII H, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis[J]. Proteomics Clin Appl, 2013, 7(9-10):648-656. doi:  10.1002/prca.201200137
[9] YOSHIHIRO, KAMADA, MASAFUMI, et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers[J]. Hepatology, 2015, 62(5):1433-1443. doi:  10.1002/hep.28002
[10] KIYOAKI I, SUMIDA Y, NAKADE Y, et al. Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis[J]. PLoS One, 2022, 17(11):e0277380. doi:  10.1371/journal.pone.0277380
[11] MA X, LIU S, ZHANG J, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1):10. doi:  10.1186/s12876-020-1165-z
[12] MOFRAD P, CONTOS M J, HAQUE M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values[J]. Hepatology, 2003, 37(6):1286-1292. doi:  10.1053/jhep.2003.50229
[13] TORRES D M, HARRISON S A. NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9):510-511. doi:  10.1038/nrgastro.2013.138
[14] NEWTON K P, LAVINE J E, WILSON L, et al. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis[J]. Hepatology, 2021, 73(3):937-951. doi:  10.1002/hep.31317
[15] ZHANG Y, HE H, ZENG Y P, et al. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study[J]. Lipids Health Dis, 2020, 19(1):134. doi:  10.1186/s12944-020-01310-x
[16] TANWAR S, TREMBLING P M, GUHA I N, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57(1):103-111. doi:  10.1002/hep.26030
[17] ZHOU Y, OREŠIČ M, LEIVONEN M, et al. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites[J]. Clin Gastroenterol Hepatol, 2016, 14(10):1463-1472. doi:  10.1016/j.cgh.2016.05.046
[18] XIAO G, ZHU S, XIAO X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis[J]. Hepatology, 2017, 66(5):1486-1501. doi:  10.1002/hep.29302
[19] SANYAL A J, RATZIU V, GOODMAN Z, et al. 507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis(NASH)in Clinical Trials - The CENTAUR Trial Data[J]. Gastroenterology, 2016, 150(4):S1037-S1038.
[20] MCPHERSON S, HARDY T, DUFOUR J F, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis[J]. Am J Gastroenterol, 2017, 112(5):740-751. doi:  10.1038/ajg.2016.453
[21] AMPUERO J, ALLER R, GALLEGO-DURAN R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH[J]. J Hepatol, 2020, 73(1):17-25. doi:  10.1016/j.jhep.2020.02.028
[22] KOGACHI S, NOUREDDIN M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis[J]. Clin Ther, 2021, 43(3):455-472. doi:  10.1016/j.clinthera.2021.01.012
[23] DANIELS S J, LEEMING D J, ESLAM M, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis[J]. Hepatology, 2019, 69(3):1075-1086. doi:  10.1002/hep.30163
[24] NIELSEN M J, LEEMING D J, GOODMAN Z, et al. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population[J]. J Hepatol, 2021, 75(6):1292-1300. doi:  10.1016/j.jhep.2021.08.016
[25] BOYLE M, TINIAKOS D, SCHATTENBERG J M, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease[J]. JHEP Rep, 2019, 1(3):188-198. doi:  10.1016/j.jhepr.2019.06.004
[26] CANIVET C M, COSTENTIN C, IRVINE K M, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD[J]. Hepatology, 2023, 77(3):920-930. doi:  10.1002/hep.32665
[27] VAN DIJK A M, VALI Y, MAK A L, et al. Systematic review with meta-analyses: diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease[J]. J Clin Med, 2021, 10(13):2910. doi:  10.3390/jcm10132910
[28] GUHA I N, PARKES J, RODERICK P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers[J]. Hepatology, 2008, 47(2):455-460.
[29] STAUFER K, HALILBASIC E, SPINDELBOECK W, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease[J]. United European Gastroenterol J, 2019, 7(8):1113-1123. doi:  10.1177/2050640619865133
[30] AMPUERO J, PAIS R, ALLER R, et al. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis[J]. Clin Gastroenterol Hepatol, 2020, 18(1):216-225. doi:  10.1016/j.cgh.2019.05.051
[31] CHONG S E, CHANG F, CHUAH K H, et al. Validation of the Hepamet fibrosis score in a multi-ethnic Asian population[J]. Ann Hepatol, 2023, 28(2):100888. doi:  10.1016/j.aohep.2022.100888
[32] AMPUERO J, ALLER R, GALLEGO-DURáN R, et al. PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD[J]. Journal of Hepatology, 2019, 70(1):e133-e134.
[33] HIGUERA-DE-LA-TIJERA F, CóRDOVA-GALLARDO J, BUGANZA-TORIO E, et al. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value[J]. Dig Dis Sci, 2021, 66(12):4501-4507. doi:  10.1007/s10620-020-06821-2
[34] MOSCA A, DELLA VOLPE L, ALISI A, et al. Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease[J]. Front Pediatr, 2022, 10:885576. doi:  10.3389/fped.2022.885576
[35] MUNTEANU M, TINIAKOS D, ANSTEE Q, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference[J]. Aliment Pharmacol Ther, 2016, 44(8):877-889. doi:  10.1111/apt.13770
[36] EUROPEAN ASSOCIATION FOR THE STUDY OF THE L, EUROPEAN ASSOCIATION FOR THE STUDY OF D, EUROPEAN ASSOCIATION FOR THE STUDY OF O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64(6):1388-1402. doi:  10.1016/j.jhep.2015.11.004
[37] VALI Y, LEE J, BOURSIER J, et al. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis[J]. J Clin Med, 2021, 10(11):2415. doi:  10.3390/jcm10112415
[38] ADAMS L A, GEORGE J, BUGIANESI E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2011, 26(10):1536-1543. doi:  10.1111/j.1440-1746.2011.06774.x
[39] SPANN A, YASODHARA A, KANG J, et al. Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review[J]. Hepatology, 2020, 71(3):1093-1105. doi:  10.1002/hep.31103
[40] STAELS B, BUTRUILLE L, FRANCQUE S. Treating NASH by targeting peroxisome proliferator-activated receptors[J]. J Hepatol, 2023, 79(5):1302-1316. doi:  10.1016/j.jhep.2023.07.004
[41] RIGANO D, SIRIGNANO C, TAGLIALATELA-SCAFATI O. The potential of natural products for targeting PPARα[J]. Acta Pharm Sin B, 2017, 7(4):427-438. doi:  10.1016/j.apsb.2017.05.005
[42] JANI R H, PAI V, JHA P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy(PRESS VI)[J]. Diabetes Technol Ther, 2014, 16(2):63-71. doi:  10.1089/dia.2013.0253
[43] GAWRIEH S, NOUREDDIN M, LOO N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial[J]. Hepatology, 2021, 74(4):1809-1824. doi:  10.1002/hep.31843
[44] FRANCQUE S M, BEDOSSA P, RATZIU V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH[J]. N Engl J Med, 2021, 385(17):1547-1558. doi:  10.1056/NEJMoa2036205
[45] LI Q X, GAO H, GUO Y X, et al. GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH[J]. Front Endocrinol(Lausanne), 2021, 12:721198. doi:  10.3389/fendo.2021.721198
[46] ARMSTRONG M J, GAUNT P, AITHAL G P, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019):679-690. doi:  10.1016/S0140-6736(15)00803-X
[47] NEWSOME P N, BUCHHOLTZ K, CUSI K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis[J]. N Engl J Med, 2021, 384(12):1113-1124. doi:  10.1056/NEJMoa2028395
[48] LI Y, JADHAV K, ZHANG Y. Bile acid receptors in non-alcoholic fatty liver disease[J]. Biochem Pharmacol, 2013, 86(11):1517-1524. doi:  10.1016/j.bcp.2013.08.015
[49] YOUNOSSI Z M, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215):2184-2196. doi:  10.1016/S0140-6736(19)33041-7
[50] CHANG Y, JEONG S W, JANG J Y. Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease[J]. Clin Mol Hepat, 2024, 30(1):129-133.
[51] KANNT A, WOHLFART P, MADSEN A N, et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis[J]. Br J Pharmacol, 2021, 178(12):2412-2423. doi:  10.1111/bph.15427
[52] WANG X, WANG L, GENG L, et al. Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner[J]. Int J Mol Sci, 2023, 24(6):5843. doi:  10.3390/ijms24065843
[53] HARRISON S A, BASHIR M R, GUY C D, et al. Resmetirom (MGL-3196)for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213):2012-2024. doi:  10.1016/S0140-6736(19)32517-6
[54] HARRISON S A, BASHIR M, MOUSSA S E, et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH[J]. Hepatol Commun, 2021, 5(4):573-588. doi:  10.1002/hep4.1657
[55] WANG Y, YU W, LI S, et al. Acetyl-CoA Carboxylases and Diseases[J]. Front Oncol, 2022, 12:836058. doi:  10.3389/fonc.2022.836058
[56] BERGMAN A, CARVAJAL-GONZALEZ S, TARABAR S, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor(PF-05221304): A Three-Part Randomized Phase 1 Study[J]. Clin Pharmacol Drug Dev, 2020, 9(4):514-526. doi:  10.1002/cpdd.782
[57] CALLE R A, AMIN N B, CARVAJAL-GONZALEZ S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials[J]. Nat Med, 2021, 27(10):1836-1848. doi:  10.1038/s41591-021-01489-1
[58] ESLER W, ROSS T, BERGMAN A, et al. PS-109-Partial inhibition of de novo lipogenesis with the acetyl-CoA carboxylase inhibitor PF-05221304 does not increase circulating triglycerides in humans and is sufficient to lower steatosis in rats[J]. J Hepatol, 2019, 70(1):e69.
[59] CHALASANI N, ABDELMALEK M F, GARCIA-TSAO G, et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension[J]. Gastroenterology, 2020, 158(5):1334-1345. doi:  10.1053/j.gastro.2019.11.296
[60] HOOFNAGLE J H, VAN NATTA M L, KLEINER D E, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2013, 38(2):134-143. doi:  10.1111/apt.12352
[61] ZEIN C O, YERIAN L M, GOGATE P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial[J]. Hepatology, 2011, 54(5):1610-1619. doi:  10.1002/hep.24544
[62] NELSON C H, ETCHEVERS K, YI S, et al. Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1(ASK1)Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects[J]. Clin Pharmacokinet, 2020, 59(9):1109-1117. doi:  10.1007/s40262-020-00878-y
[63] LOOMBA R, LAWITZ E, MANTRY P S, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67(2):549-559. doi:  10.1002/hep.29514
[64] HARRISON S A, WONG V W, OKANOUE T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials[J]. J Hepatol, 2020, 73(1):26-39. doi:  10.1016/j.jhep.2020.02.027
[65] POCKROS P J, FUCHS M, FREILICH B, et al. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients[J]. Liver Int, 2019, 39(11):2082-2093. doi:  10.1111/liv.14209
[66] CHOI Y J, JOHNSON J D, LEE J J, et al. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis[J]. Am J Physiol Gastrointest Liver Physiol, 2024, 326(2):G120-g132. doi:  10.1152/ajpgi.00158.2023
[67] ALKHOURI N, HERRING R, KABLER H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial[J]. J Hepatol, 2022, 77(3):607-618. doi:  10.1016/j.jhep.2022.04.003